Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial
Sign Up to like & getrecommendations! Published in 2023 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022009389
Abstract: Key Points • In the PHOENIX trial, the addition of ibrutinib to R-CHOP did not improve the survival of patients with previously untreated non-GCB DLBCL.• This study identified a patient subset with high BCL2/MYC coexpression… read more here.
Keywords: chop; dlbcl; bcl2 myc; clinical impact ... See more keywords
Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors
Sign Up to like & getrecommendations! Published in 2019 at "PLoS ONE"
DOI: 10.1371/journal.pone.0224247
Abstract: Aberrant expression of CD5 has been reported in 5–10% of diffuse large B-cell lymphomas (DLBCLs). CD5+ DLBCL had been recognized as an aggressive immunophenotypic subgroup of DLBCL in the 2008 WHO classification of haematolymphoid neoplasm;… read more here.
Keywords: cd5; dlbcls; bcl2 myc; large cell ... See more keywords